Rare 'Skinny Gene' Mutation May Explain Natural Weight Loss in Some Individuals

A rare genetic mutation in the FNIP1 gene may be responsible for why some individuals naturally maintain a slim physique and have a lower risk of metabolic conditions, according to a new study. This mutation affects how the body regulates cellular energy and metabolism, leading to increased calorie burning.

The research, published in the journal Nature, analyzed genetic data from over one million people across North America, Europe, and Asia. Scientists identified approximately 150 participants with a specific FNIP1 mutation. These individuals exhibited lower blood sugar, decreased cholesterol, reduced liver fat, and a roughly 60 percent lower risk of developing metabolic diseases such as obesity and type 2 diabetes.

"These individuals consume, store and utilize energy more efficiently than individuals without those mutations, and that's the protective factor," Luca Lotta, a study co-senior author and geneticist at Regeneron Pharmaceuticals, told Scientific American. "Nowadays, we are living in a very calorie-rich environment, and historically there’s no precedent for this."

This mutation affects approximately one in 7,000 people globally, translating to about one million individuals worldwide. Researchers estimate that around 48,000 Americans carry this genetic variation. The study suggests that this enhanced metabolic efficiency, unrelated to diet or exercise, is the key factor in maintaining a lower body weight and improving metabolic health.

Experiments on mice further supported these findings. When FNIP1 was silenced in liver cells, fat-burning genes were activated. In mice fed a high-fat, high-sugar diet, altering the gene helped curb weight gain, reduce fat accumulation, and improve insulin sensitivity. Over a 30-week period, this intervention also prevented liver scarring.

However, the study also noted a crucial distinction: inheriting two mutated copies of FNIP1, rather than just one, did not confer the same benefits. Instead, it increased vulnerability to heart disease and immune deficiency, highlighting the delicate balance of genetic expression.

While the findings offer new insights into natural weight regulation and metabolic health, therapeutic applications are still distant. Lotta cautioned that directly inhibiting the gene throughout the body could have adverse health effects. Targeting the gene specifically in the liver might mitigate risks, but he stressed that any potential therapies are "many years away."

Genetic sequencing tests to determine the presence of this mutation can range from $1,000 to $2,000 out of pocket, depending on insurance coverage. The researchers believe their work could eventually inform the development of new weight-loss medications that mimic the effects of existing drugs like GLP-1 agonists, but through a novel genetic pathway.